Aware Super Pty Ltd as trustee of Aware Super Makes New $630,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aware Super Pty Ltd as trustee of Aware Super bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,211 shares of the medical research company’s stock, valued at approximately $630,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. Nordea Investment Management AB raised its holdings in shares of Thermo Fisher Scientific by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company’s stock valued at $28,868,000 after acquiring an additional 10,606 shares in the last quarter. S.E.E.D. Planning Group LLC lifted its position in Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock valued at $5,528,000 after purchasing an additional 618 shares during the last quarter. Czech National Bank grew its stake in Thermo Fisher Scientific by 6.6% in the 4th quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after buying an additional 5,118 shares in the last quarter. Douglas Lane & Associates LLC raised its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock valued at $94,948,000 after buying an additional 3,460 shares in the last quarter. Finally, M&T Bank Corp grew its position in Thermo Fisher Scientific by 4.2% in the third quarter. M&T Bank Corp now owns 113,347 shares of the medical research company’s stock worth $70,113,000 after acquiring an additional 4,584 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 in the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $440.91 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The stock has a market cap of $166.44 billion, a price-to-earnings ratio of 26.67, a PEG ratio of 2.99 and a beta of 0.86. The stock’s 50 day simple moving average is $505.28 and its two-hundred day simple moving average is $536.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.41%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on TMO shares. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a report on Friday, January 31st. Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Citigroup lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $647.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.